Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G75226103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Nantahala Capital Management, LLC
13G
|
14.1% |
10/7/2026
Event 9/30/2026
|
|
| Nantahala Capital Management, LLC | 14.1% | ||
| Wilmot B. Harkey | 14.1% | ||
| Daniel Mack | 14.1% | ||
|
Great Point Partners, LLC
13G
|
6.5% |
9/11/2026
Event 9/4/2026
|
|
| Great Point Partners, LLC | 6.5% | ||
| Dr. Jeffrey R. Jay, M.D. | 6.5% | ||
| Ms. Lillian Nordahl | 6.5% | ||
|
TCG Crossover GP III, LLC
13G
|
6.4% |
8/14/2026
Event 6/30/2026
|
|
| TCG Crossover GP III, LLC | 6.4% | ||
| TCG Crossover Fund III, L.P. | 6.4% | ||
| Chen Yu | 6.4% | ||
|
Balyasny Asset Management L.P.
13G
|
6.4% |
8/14/2026
Event 6/30/2026
|
|
| Balyasny Asset Management L.P. | 6.4% | ||
| Bam GP LLC | 6.4% | ||
| Balyasny Asset Management Holdings LP | 6.4% | ||
| Dames GP LLC | 6.4% | ||
| Dmitry Balyasny | 6.4% | ||
|
ADAR1 Capital Management, LLC
13G
|
8.4% |
8/14/2026
Event 6/30/2026
|
|
| ADAR1 Capital Management, LLC | 8.4% | ||
| Daniel Schneeberger | 8.4% | ||
|
Spruce Street Capital LP
13G
|
6.4% |
8/13/2026
Event 6/30/2026
|
|
| Spruce Street Capital LP | 6.4% | ||
| Alex R. Rosen | 6.4% | ||
| Simon Basseyn | 6.4% | ||
| Bank of America Corp /DE/ 13G | 6.5% |
8/3/2026
Event 6/30/2026
|
|
|
Research Alliance Holdings III LLC /Cayman
13D/A
Amendment 1
|
16.9% |
7/28/2026
Event 7/26/2026
|
|
| Research Alliance Holdings III LLC | 16.9% | ||
| Matthew Hammond | 16.9% | ||
|
Research Alliance Holdings III LLC /Cayman
13D
|
14.7% |
5/29/2026
Event 5/21/2026
|
|
| Research Alliance Holdings III LLC | 14.7% | ||
| Matthew Hammond | 14.7% | ||
|
Trails Edge Capital Partners, LP
13G
|
5.5% |
5/29/2026
Event 5/21/2026
|
|
| Trails Edge Capital Partners, LP | 5.5% | ||
| Trails Edge Biotechnology Master Fund, LP | 5.5% | ||
| Ortav Yehudai | 5.5% | ||
|
Biotechnology Value Fund L P
13G
|
6.4% |
5/29/2026
Event 5/21/2026
|
|
| Biotechnology Value Fund L P | 3.4% | ||
| BVF I GP LLC | 3.4% | ||
| Biotechnology Value Fund II LP | 2.5% | ||
| BVF II GP LLC | 2.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 5.9% | ||
| BVF Partners L P/IL | 6.4% | ||
| BVF Inc/IL | 6.4% | ||
| Lampert Mark N | 6.4% | ||
|
Commodore Capital LP
13G
|
5.5% |
5/28/2026
Event 5/20/2026
|
|
| Commodore Capital LP | 5.5% | ||
| Commodore Capital Master LP | 5.5% | ||
| Robert Egen Atkinson | 5.5% | ||
| Michael Kramarz | 5.5% | ||
|
Perceptive Advisors LLC
13G
|
8.2% |
5/28/2026
Event 5/20/2026
|
|
| Perceptive Advisors LLC | 8.2% | ||
| Joseph Edelman | 8.2% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 23 | 7.43 M | $79.6 M |